Pieris Pharmaceuticals, INC Form 4 insider transactions
Pieris Pharmaceuticals issued a single share of Series F Preferred Stock to its Chairman, James Geraghty, for $1.00 to ensure a favorable vote on a future proposal to increase the company's authorized common stock.
425: Pieris Pharmaceuticals to Merge with Palvella Therapeutics, Creating Rare Disease Focused Company
Pieris Pharmaceuticals and Palvella Therapeutics have announced a definitive merger agreement to form a clinical-stage biopharmaceutical company focused on rare genetic skin diseases.